Referenser

  1. Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405-19.

  2. Proceedings of a symposium. Consensus Development Conference on Osteoporosis. October 19-20, 1990, Copenhagen, Denmark. Am J Med. 1991;91(5B):1S-68S.

  3. Willers C, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, et al. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022;17(1):23.

  4. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int. 2000;11(8):669-74.

  5. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med. 2003;348(1):42-9.

  6. Voermans NC, Snijders AH, Schoon Y, Bloem BR. Why old people fall (and how to stop them). Pract Neurol. 2007;7(3):158-71.

  7. Kanis JA, Johansson H, McCloskey EV, Liu E, Akesson KE, Anderson FA, et al. Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. Osteoporos Int. 2023;34(12):2027-45.

  8. Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013;24(8):2135-52.

  9. Nationellt system för kunskapsstyrning hälso- och sjukvård. Personcentrerat och Personcentrerat och sammanhållet vårdförlopp - sekundärprevention efter fraktur. Stockholm2021 [Available from: https://kunskapsstyrningvard.se/kunskapsstyrningvard/kunskapsstod/publiceradekunskapsstod/endokrinasjukdomar/osteoporosvardforlopp.64365.html.

  10. Axelsson KF, Johansson H, Lundh D, Moller M, Lorentzon M. Association Between Recurrent Fracture Risk and Implementation of Fracture Liaison Services in Four Swedish Hospitals: A Cohort Study. J Bone Miner Res. 2020;35(7):1216-23.

  11. Wu C-H, Tu S-T, Chang Y-F, Chan D-C, Chien J-T, Lin C-H, et al. Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: A systematic literature review and meta-analysis. Bone. 2018;111:92-100.

  12. Melton LJ, 3rd. Epidemiology of spinal osteoporosis. Spine (Phila Pa 1976). 1997;22(24 Suppl):2S-11S.

  13. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137-48.

  14. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Mortality after osteoporotic fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2004;15(1):38-42.

  15. Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest. 2024;47(3):501-11.

  16. Borgstrom F, Karlsson L, Ortsater G, Norton N, Halbout P, Cooper C, et al. Fragility fractures in Europe: burden, management and opportunities. Archives of osteoporosis. 2020;15(1):59.

  17. van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2002;13(10):777-87.

  18. Nethander M, Moverare-Skrtic S, Kampe A, Coward E, Reimann E, Grahnemo L, et al. An atlas of genetic determinants of forearm fracture. Nat Genet. 2023;55(11):1820-30.

  19. Minaire P. Immobilization osteoporosis: a review. Clin Rheumatol. 1989;8 Suppl 2:95-103.

  20. Yeung SSY, Reijnierse EM, Pham VK, Trappenburg MC, Lim WK, Meskers CGM, et al. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(3):485-500.

  21. Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLoS One. 2017;12(4):e0174730.

  22. Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014;6(5):185-202.

  23. Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, et al. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom. 2019;22(4):453-71.

  24. Mackey DC, Lui L-Y, Cawthon PM, Bauer DC, Nevitt MC, Cauley JA, et al. High-trauma fractures and low bone mineral density in older women and men. Jama. 2007;298(20):2381-8.

  25. Borges JLC, de M Miranda IS, Lewiecki EM. The Clinical Utility of Vertebral Fracture Assessment in Predicting Fractures. J Clin Densitom. 2017;20(3):304-8.

  26. Brinckman MA, Chau C, Ross JS. Marrow edema variability in acute spine fractures. Spine J. 2015;15(3):454-60.

  27. Nationellt system för kunskapsstyrning hälso- och sjukvård. Nationellt vårdprogram för primär hyperparatyreoidism 2023 [Available from: https://kunskapsstyrningvard.se/kunskapsstyrningvard/kunskapsstod/publiceradekunskapsstod/endokrinasjukdomar/hyperparatyreoidismprimarvardprogram.72181.html

  28. Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(1):33-41.

  29. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Jama. 1999;282(14):1344-52.

  30. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England journal of medicine. 2007;356(18):1809-22.

  31. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118-24.

  32. Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230-40.

  33. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. The New England journal of medicine. 2017;377(15):1417-27.

  34. Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab. 2022;66(5):724-38.

  35. Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. The New England journal of medicine. 2018;379(25):2407-16.

  36. Bolland MJ, Nisa Z, Mellar A, Gasteiger C, Pinel V, Mihov B, et al. Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age. The New England journal of medicine. 2025;392(3):239-48.

  37. Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. Cmaj. 2017;189(36):E1130-E6.

  38. Turner NM, Mayeda MS, De Lima B, Friess D, Doung Y-C, Drago K. A Hip New Standard: Improving Osteoporosis Care with Inpatient Administration of IV Zoledronate. J Bone Joint Surg Am. 2025;107(7):709-16.

  39. Malgo F, van Deudekom FJA, Hup R, Formijne Jonkers HA, Kempen DHR, de Vries K, et al. Inpatient zoledronic acid in older hip fracture patients is well tolerated and safe. Archives of osteoporosis. 2024;19(1):96.

  40. Fan W, Sun X, Leder BZ, Lee H, Ly TV, Pu CT, et al. Zoledronic acid for hip fracture during initial hospitalization. J Bone Miner Res. 2024;39(8):1061-70.

  41. Tsourdi E, Zillikens MC, Meier C, Body J-J, Gonzalez Rodriguez E, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020.

  42. Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, et al. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. J Clin Endocrinol Metab. 2022;107(5):1441-60.

  43. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267-94.

  44. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23.

  45. Black DM, Eastell R, Adams AL. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. Reply. The New England journal of medicine. 2020;383(22):2189-90.

  46. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. The New England journal of medicine. 2011;364(18):1728-37.

  47. Meier RPH, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172(12):930-6.

  48. Wang M, Wu Y-F, Girgis CM. Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real-World Studies. JBMR Plus. 2022;6(6):e10629.

  49. Bogdan Y, Tornetta P, 3rd, Einhorn TA, Guy P, Leveille L, Robinson J, et al. Healing Time and Complications in Operatively Treated Atypical Femur Fractures Associated With Bisphosphonate Use: A Multicenter Retrospective Cohort. J Orthop Trauma. 2016;30(4):177-81.

  50. Githens M, Garner MR, Firoozabadi R. Surgical Management of Atypical Femur Fractures Associated With Bisphosphonate Therapy. J Am Acad Orthop Surg. 2018;26(24):864-71.

  51. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-622.

  52. Sherrington C, Fairhall NJ, Wallbank GK, Tiedemann A, Michaleff ZA, Howard K, et al. Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2019;1:CD012424.

  53. Clemson L, Stark S, Pighills AC, Fairhall NJ, Lamb SE, Ali J, et al. Environmental interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2023;3:CD013258.

  54. Cameron ID, Dyer SM, Panagoda CE, Murray GR, Hill KD, Cumming RG, et al. Interventions for preventing falls in older people in care facilities and hospitals. Cochrane Database Syst Rev. 2018;9:CD005465.

  55. Socialstyrelsen. Nationella riktlinjer för rörelseorganens sjukdomar 2021 [Available from: https://www.socialstyrelsen.se/kunskapsstod-och-regler/regler-och-riktlinjer/nationella-riktlinjer/riktlinjer-och-utvarderingar/rorelseorganens-sjukdomar/

  56. Brooke-Wavell K, Skelton DA, Barker KL, Clark EM, De Biase S, Arnold S, et al. Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis. Br J Sports Med. 2022;56(15):837-46.

Föregående sida
Behandling

Nästa sida
Tillbaka till kapitlets första sida